Despite significant progress, several challenges hinder the acceleration of innovation in cancer research. These include regulatory hurdles, the high cost of drug development, and limited access to cutting-edge treatments for certain populations. Additionally, the complexity of cancer biology means that many promising therapies fail to translate into clinical success. Addressing these challenges requires a multi-faceted approach, including policy reform, increased funding, and a commitment to equity in healthcare.
